This index provides a navigation layer for non-profit organizations, advocacy groups, and research foundations focused on neurodegenerative disease research. These organizations play critical roles in funding research, supporting patients and families, and advancing our understanding of disease mechanisms.
Total: 26 pages
- AC Immune — Swiss biotech, tau immunotherapy](/organizations)
- Alector — US biotech, TREM2/progranulin](/organizations)
- Asceneuron — Swiss biotech, tau aggregation inhibitors](/organizations)
- BioArctic — Swedish biotech, tau, 4R-tauopathy](/organizations)
- CurePSP — US nonprofit, progressive supranuclear palsy](/organizations)
- Denali Therapeutics — US biotech, LRRK2, Parkin, TREM2](/organizations)
- Lundbeck — Danish pharma, neuroscience](/organizations)
- PSP France — French advocacy, progressive supranuclear palsy](/organizations)
- PSP Germany — German advocacy, progressive supranuclear palsy](/organizations)
- Takeda — Japanese pharma, tau, Parkinson's](/organizations)
- Tau Consortium — Research consortium, tau biology](/organizations)
- Angelman Syndrome Foundation — US nonprofit, Angelman syndrome research](/organizations)
- CDKL5 Alliance — International alliance, CDKL5 deficiency](/organizations)
- Dravet Syndrome Foundation — US nonprofit, Dravet syndrome and epilepsy](/organizations)
- KCNQ2 Cure Foundation — US nonprofit, KCNQ2 epilepsy](/organizations)
- PCDH19 Family Network — US nonprofit, PCDH19 clustering epilepsy](/organizations)
- PSP Australia — Australian advocacy, progressive supranuclear palsy](/organizations)
- PSP Canada — Canadian advocacy, progressive supranuclear palsy](/organizations)
- PSP Italy — Italian advocacy, progressive supranuclear palsy](/organizations)
- PSP Japan — Japanese advocacy, progressive supranuclear palsy](/organizations)
- PSP Netherlands — Dutch advocacy, progressive supranuclear palsy](/organizations)
- PSP UK — UK advocacy, progressive supranuclear palsy](/organizations)
- SLC6A1 Connect — US nonprofit, SLC6A1 mutation advocacy](/organizations)
- STXBP1 Foundation — US nonprofit, STXBP1 encephalopathy
- Companies — Pharma and biotech companies (475 pages)
- Institutions — Research universities and hospitals (291 pages)](/institutions)
- Researchers — Key investigators (203 pages)](/researchers)
- Diseases — Disease-specific organizations